Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Government Doctors Make Gross Errors Concerning Measles Statistics, Misinform Senators, Threaten Public Health

Physicians for Informed Consent doctors and scientists sound alarm as legislators consider banning physicians from making personalized vaccine recommendations in California.


News provided by

Physicians for Informed Consent

May 03, 2019, 09:00 ET

Share this article

Share toX

Share this article

Share toX

Dr. Alexander Langmuir - CDC Director 1949-1970
Dr. Alexander Langmuir - CDC Director 1949-1970
Youtube
Youtube

NEWPORT BEACH, Calif., May 3, 2019 /PRNewswire-PRWeb/ -- Physicians for Informed Consent (PIC), an organization of doctors and scientists who encourage using statistics to safeguard public health, recently flew in doctors from across California to educate members of the Senate Committee on Health about the risks of measles vs. the risks of the measles, mumps, and rubella (MMR) vaccine—which are explained in PIC's opposition letter [1] to California SB 276, a bill that would allow only state public health officers the right to grant or approve vaccine exemptions to children at-risk of vaccine injuries.[2] PIC's doctors included Dr. Shira Miller, Dr. Lionel Lee, Dr. Edmond Sarraf, Dr. Melanie Gisler, and Dr. Charles Penick.

At the Senate Committee on Health hearing for SB 276, on April 24, 2019, Dr. Erica Pan, interim health officer at Alameda County Public Health Department, testified to senators that 1 in 1,000 measles cases result in death, a figure that contradicts measles death statistics by 10-fold from the pre-vaccine era.[3] As Dr. Alexander Langmuir, director of the epidemiology branch of the Communicable Disease Center (now Centers for Disease Control and Prevention) for 21 years, explained in his seminal 1962 paper,[4] measles is a "self-limiting infection of short duration, moderate severity, and low fatality," and "…in the United States measles is a disease whose importance is not to be measured by total days disability or number of deaths."

…in the United States measles is a disease whose importance is not to be measured by total days disability or number of deaths.

Post this

Between 1959 and 1962, before the introduction of the measles vaccine, about 400 measles deaths among approximately 4 million measles cases occurred every year in the United States, which results in a 1 in 10,000 (0.01%) chance of a child dying from measles, not 1 in 1,000. This information is explained in detail in the PIC educational documents, the Measles Disease Information Statement (DIS)[3] and Vaccine Risk Statement (VRS),[5] which were provided to all California legislators.

By comparison, over 23,000 infant deaths occur every year in the U.S. from all causes and the chance of a child dying in his or her first year of life is currently 1 in 170 (0.6%)[6]—which is 60 times the risk of a child dying from measles in 1962, a time period when almost every child had measles by age 15.[3]

Now, misinformation concerning measles data is rampant. On April 29, 2019, Dr. Robert Redfield, director of the Centers for Disease Control and Prevention since 2018, stated in a CDC telebriefing that, "There are no treatment and no cure for measles and no way to predict how bad a case of measles will be."[7] However, Dr. Redfield's statement is erroneous. High-dose vitamin A and immunoglobulin (passive immunization) are available for the treatment of measles upon exposure,[3] there is evidence that the antiviral ribavirin is beneficial in the treatment of measles,[8-10] and 99.99% of measles cases fully recover.[3] Additionally, 75–92% of hospitalized measles cases are low in vitamin A, and vitamin A status is a known factor that can be used to predict the severity of measles.[3]

"Misrepresenting the measles death rate by 10-fold is dangerous because it prevents one from accurately comparing the risk of measles vs. the risk of the MMR vaccine," said Dr. Shira Miller, PIC founder and president. "If a doctor doesn't know the true risk of serious harm from measles and doesn't know that effective measles treatments are available, how can he or she determine which children are more at-risk of vaccine injury than being harmed by a measles infection?"

One of the risks of the MMR vaccine is seizure, which occurs in up to 1 in 641 vaccinated children, 1 in 252 vaccinated siblings of children with a history of febrile seizures, and 1 in 51 vaccinated children with a personal history of febrile seizures;[11] with 5% of febrile seizures resulting in epilepsy.[12] Furthermore, a review of more than 60 MMR vaccine studies conducted for the Cochrane Library states, "The design and reporting of safety outcomes in MMR vaccine studies, both pre- and post-marketing, are largely inadequate."[13]

"There are more ethical solutions to the rare complications that occur from measles in the United States than banning physicians from making personalized vaccine recommendations for their patients," said Dr. Miller.

Physicians for Informed Consent is a nationally recognized 501(c)(3) nonprofit educational organization representing doctors and scientists whose mission is to safeguard informed consent in vaccination. In addition, PIC's Coalition for Informed Consent consists of more than 150 U.S. and international organizations. Visit physiciansforinformedconsent.org for more information.

References

1.    https://physiciansforinformedconsent.org/pic-opposes-sb-276-letter-to-california-legislators/
2.    http://leginfo.legislature.ca.gov/faces/billAnalysisClient.xhtml?bill_id=201920200SB276
3.    https://physiciansforinformedconsent.org/measles/dis/
4.    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1522578/
5.    https://physiciansforinformedconsent.org/measles/vrs/
6.    https://www.cdc.gov/nchs/products/databriefs/db293.htm
7.    https://www.cdc.gov/media/releases/2019/t0429-national-update-measles.html
8.    https://www.ncbi.nlm.nih.gov/pubmed/22480102
9.    https://www.ncbi.nlm.nih.gov/pubmed/7008941
10.    https://www.ncbi.nlm.nih.gov/pubmed/23629813
11.    https://www.ncbi.nlm.nih.gov/pubmed/15265850
12.    https://academic.oup.com/aje/article/165/8/911/184889
13. https://www.ncbi.nlm.nih.gov/pubmed/22336803

###

SOURCE Physicians for Informed Consent

Related Links

http://www.physiciansforinformedconsent.org

Modal title

Measles - What Parents Need to Know
View PDF
Measles - What Parents Need to Know
MMR Vaccine - Is It Safer Than Measles?
View PDF
MMR Vaccine - Is It Safer Than Measles?
Vaccines: What About Immunocompromised Schoolchildren?
View PDF
Vaccines: What About Immunocompromised Schoolchildren?
The Importance of Measles as a Health Problem
View PDF
The Importance of Measles as a Health Problem
Measles - What Parents Need to Know MMR Vaccine - Is It Safer Than Measles? Vaccines: What About Immunocompromised Schoolchildren? The Importance of Measles as a Health Problem

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.